Soleus Private Equity Fund III and Affiliates Acquire 9.99% Stake in Aprea Therapeutics via Warrants

On April 1, 2026, a group of reporting entities led by Soleus Private Equity Fund III, L.P. and managed by Guy Levy filed a Schedule 13G regarding their holdings in Aprea Therapeutics, Inc. (APRE). The filing reveals a new beneficial ownership position of 1,271,080 shares of common stock, representing 9.99% of the company's outstanding shares. This position consists of shares issuable upon the exercise of pre-funded warrants and common warrants held directly by Soleus Private Equity Fund III, L.P. and Soleus Capital Master Fund, L.P. The reported share count reflects the maximum number of shares permitted under beneficial ownership limitations set forth in the warrants. The reporting group includes various Soleus-affiliated entities such as Soleus Capital Management, L.P. and Soleus Private Equity GP III, LLC, all of which share voting and dispositive power over the securities. The filing indicates that the securities were acquired for investment purposes and not to influence or change the control of the issuer.